



Sheet 1 of 2

<b>Form PTO-1019</b> <b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>	<b>ATTY. DOCKET NO.</b> P30693C4X1C1 RCE	<b>SERIAL NO.</b> 09/922,067
	<b>APPLICANT</b> MacPhee, et al.	
	<b>FILING DATE</b> Herewith	<b>GROUP</b> 1652

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
mmml	AA	5,527,698	6-96	Knopf, et al.			
	AB	5,532,152	7-96	Cousens et al.			
	AC	5,641,669	6-97	Cousens et al.			
	AD	5,981,252	11-99	MacPhee, et al			
	AE	5,968,818	10-99	Gloger, et al.			
	AF	5,840,839	11-98	Wang, et al.			
	AG	10/415,682	05-03	Campbell, et al.			
mmml	AH	11/141,554	05-05	MacPhee, et al.			

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation Yes   No	
mmml	BA	0359425 A1	29-08-88	EPO				
	BB	WO89/09818	19-10-89	PCT				
	BC	0509719 A1	21-10-92	EPO				
mmml	BD	WO95/00649	05-01-95	PCT				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

mmml	CA	Chandrakumar NS, et al., "Stereospecific Synthesis of Ether Phospholipids. Preparation of $\alpha$ -Alkyl-2-(acylamino)-2-deoxyglycerophosphoryl cholines," <i>J. Org. Chem.</i> , 1197-1202 (1983)
	CB	Ponpipom MM, et al., "Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives," <i>Chem. Phys. Lipids</i> . 35:29-37 (1984)
	CC	Stafforini D, et al., "Human plasma platelet-activating factor acetylhydrolase," <i>J. Biol. Chem.</i> 262(9):4223-4230 (1987)
	CD	Stafforini D, et al. "Human macrophages secrete plate-activating factor acetylhydrolase," <i>J. Biol. Chem.</i> 265(17):9682-9687 (1990).
	CE	Langlais J., et al., Platelet-activating factor acetyl-hydrolase in human semen: a novel decapacitation factor?" <i>Biol. of Reprod.</i> 44 (Suppl.1):94 (1991).
	CF	San H., et al. "Safety and Short Term Toxicity of a Novel and Cationic Formulation for Human Gene Therapy," <i>Human Gene Therapy</i> : 781-798 (1993).
mmml	CG	Kim UT, et al. "Synthesis of Phospholipid Headgroups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes," <i>J. Chem. Soc. Chem. Commun.</i> : 70-71 (1993).



Sheet 2 of 2

Form PTO 449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P30693C4X1C1 RCE	SERIAL NO. 09/922,067
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		APPLICANT MacPhee, et al.	
		FILING DATE Herewith	GROUP 1652

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

mm	CH	Christofferson R, et al. "Ribozymes as Human Therapeutic Agents," <i>J. of Medicinal Chem.</i> : 2023-2037 (1994).
	CI	Stull R, et al., "Antigene, Ribozyme, and Sptomer Nucleic Acid Drugs: Progress and Prospects," <i>Pharm. Res.</i> 12(4):465-483(1995)
	CJ	Steinbrecher et al., "Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase," <i>J. Lipid Res.</i> , 30(3) :305-315 (1989)
	CK	Stremier K E, et al., "An Oxidized Derivative of Phosphatidylcholine is a Substrate for the Platelet-activating Factor Aceylhydrolase from Human Plasma," <i>J. Biol. Chem.</i> , 264(10):5331-5334 (1989)
	CL	Sevier ED, et al., "Monoclonal Antibodies in Clinical Immunology," <i>Clinical Chem.</i> 27:1797-1806 (1981)
	CM	Kohler G, et al., <i>Nature</i> 236:495-497 (1975)
	CN	Bell, Rachel, et al., "Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control polymorphic variants and case-control analysis in schizophrenia," <i>Biochemical and Biophysical Research Communications</i> , 241(3): 630-635 (1997) XP002197530
	CO	Yamada, Yoshiji, et al., "Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese Population", <i>Atherosclerosis</i> , 150(1):209-216(2000) XP002197527
	CP	Hiramoto, Maoto, et al., "A mutation in plasma platelet-activating factor acetylhydrolase (Val279fwdarwPhe) is a genetic risk factor for stroke." <i>Stroke</i> , 28(12):2417-2420 (December 12, 1997) XP002197528
	CQ	Kruse, Susanne, et al., "The Ile198Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytical activites and are associated with atopy and asthma," <i>Am. Journal of Human Genetics</i> , 66(5):1522-1530 (2000) XP002197529
	CR	Tew, D. G., et al., "Purification, properties, sequencing and cloning of a lipo-protein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins", <i>Arteriosclerosis Thrombosis and Vascular Biology</i> , 16(4):591-599 (April, 1996)
mm	CS	Tjoelker, I. W., "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase", <i>Nature, MacMillan Journals Ltd., London</i> , 374(6):549-553 (April 1995) XP002109103
EXAMINER		DATE CONSIDERED
mm		11/2/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P30693C4X1C1 RCE	SERIAL NO. 09/922,067
<b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		APPLICANT MacPhee, et al.	
		FILING DATE August 3, 2001	GROUP 1652

## U.S. PATENT DOCUMENTS


Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
mm2	AA	5,527,698	6-96	Knopf, et al.			
	AB	5,532,152	7-96	Cousens et al.			
	AC	5,641,669	6-97	Cousens et al.			
	AD	5,981,252	11-99	MacPhee, et al			
	AE	5,968,818	10-99	Gloger, et al.			
	AF	5,840,839	11-98	Wang, et al.			
	AG	10/415,682	05-03	Campbell, et al.			
mm2	AH	11/141,554	05-05	MacPhee, et al.			

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
mm2	BA	0359425 A1	29-08-88	EPO				
	BB	WO89/09818	19-10-89	PCT				
	BC	0509719 A1	21-10-92	EPO				
mm2	BD	WO95/00649	05-01-95	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

mm2	CA	Chandrakumar NS, et al., "Stereospecific Synthesis of Ether Phospholipids. Preparation of a-Alkyl-2-(acylamino)-2-deoxyglycerophosphoryl cholines," <i>J. Org. Chem.</i> , 1197-1202 (1983)
	CB	Ponpipom MM, et al., "Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives," <i>Chem. Phys. Lipids</i> , 35:29-37 (1984)
	CC	Stafforini D, et al., "Human plasma platelet-activating factor acetylhydrolase," <i>J. Biol. Chem.</i> 262(9):4223-4230 (1987)
	CD	Stafforini D, et al. "Human macrophages secrete plate-activating factor acetylhydrolase," <i>J. Biol. Chem.</i> 265(17):9682-9687 (1990).
	CE	Langlais J., et al., Platelet-activating factor acetyl-hydrolase in human semen: a novel decapacitation factor?" <i>Biol. of Reprod.</i> 44 (Suppl.1):94 (1991).
	CF	Hong S, et al. "Safety and Short Term Toxicity of a Novel Cationic Lipid Formulation for Human Gene Therapy," <i>Human Gene Therapy</i> :781-798 (1993).
mm2	CG	Kim UT, et al. "Synthesis of Phospholipid Headgroups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes," <i>J. Chem. Soc. Chem. Commun.</i> :70-71 (1993).



Sheet 2 of 2

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P30693C4X1C1 RCE	SERIAL NO. 09/922,067
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		APPLICANT MacPhee, et al.	
		FILING DATE Herewith	GROUP 1652

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

mm2	CH	Christofferson R, et al. "Ribozymes as Human Therapeutic Agents," <i>J. of Medicinal Chem.</i> : 2023-2037 (1994)
	CI	Stull R, et al., "Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects," <i>Pharm. Res.</i> 12(4):465-483(1995)
	CJ	Steinbrecher et al., "Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase," <i>J. Lipid Res.</i> , 30(3) :305-315 (1989)
	CK	Stremier K E, et al., "An Oxidized Derivative of Phosphatidylcholine is a Substrate for the Platelet-activating Factor Acetylhydrolase from Human Plasma," <i>J. Biol. Chem.</i> , 264(10):5331-5334 (1989)
	CL	Sevier ED, et al., "Monoclonal Antibodies in Clinical Immunology," <i>Clinical Chem.</i> 27:1797-1806 (1981)
	CM	Kohler G, et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <i>Nature</i> 236:495-497 (August 7, 1975)
	CN	Bell, Rachel, et al., "Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control polymorphic variants and case-control analysis in schizophrenia," <i>Biochemical and Biophysical Research Communications</i> , 241(3): 630-635 (1997) XP002197530
	CO	Yamada, Yoshiji, et al., "Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese Population", <i>Atherosclerosis</i> , 150(1):209-216(2000) XP002197527
	CP	Hiramoto, Maoto, et al., "A mutation in plasma platelet-activating factor acetylhydrolase (Val279fwdarwPhe) is a genetic risk factor for stroke." <i>Stroke</i> , 28(12):2417-2420 (December 12, 1997) XP002197528
	CQ	Kruse, Susanne, et al., "The Ile198Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytical activities and are associated with atopy and asthma," <i>Am. Journal of Human Genetics</i> , 66(5):1522-1530 (2000) XP002197529
	CR	Tew, D. G., et al., "Purification, properties, sequencing and cloning of a lipo-protein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins", <i>Arteriosclerosis Thrombosis and Vascular Biology</i> , 16(4):591-599 (April, 1996)
mm2	CS	Tjoelker, I. W., "Anti-inflammatory properties of a platelet-activating factor acetylhydrolase", <i>Nature, MacMillan Journals Ltd., London</i> , 374(6):549-553 (April 1995) XP002109103

EXAMINER  mm2	DATE CONSIDERED  11/2/05
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	